A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies is a PHASE2 clinical asset sponsored by Franziska Wachter in Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloid Malignancies, MDS, Inherited Bone Marrow Failure Syndrome, Myeloid Neoplasm, Aml. SEO and diligence focus: Decitabine, Filgrastim, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.